NAYA (NAYA Biosciences) LT-Debt-to-Total-Asset : 0.20 (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is NAYA Biosciences LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. NAYA Biosciences's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.20.

NAYA Biosciences's long-term debt to total assets ratio declined from Sep. 2023 (0.35) to Sep. 2024 (0.20). It may suggest that NAYA Biosciences is progressively becoming less dependent on debt to grow their business.

NAYA Biosciences LT-Debt-to-Total-Asset Historical Data

The historical data trend for NAYA Biosciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NAYA Biosciences LT-Debt-to-Total-Asset Chart

NAYA Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.24

0.01

0.18

0.36

0.25

NAYA Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.35	0.25	0.24	0.20	0.20

NAYA Biosciences LT-Debt-to-Total-Asset Calculation

NAYA Biosciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	4.61	/	18.506
	=	0.25

NAYA Biosciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	3.387	/	17.019
	=	0.20

NAYA Biosciences (NAS:NAYA) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

NAYA Biosciences LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of NAYA Biosciences's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

NAYA Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NAYA Biosciences Inc (NAS:NAYA) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

5582 Broadcast Court, Sarasota, FL, USA, 34240

Website

https://www.nayabiosciences.com

NAYA Biosciences operates a healthcare services fertility business as well as expand its focus to the development of first-in-class clinical-stage assets in oncology and autoimmune diseases.

Executives

Trent D Davis	director	811 SW NAITO PARKWAY, SUITE 200, PORTLAND OR 97204
Matthew K Szot	director	802 NORTH DOUTY STREET, HANFORD CA 93230
Steve Shum	director	9025 SW HILLMAN COURT, SUITE 3126, WILSONVILLE OR 97070
Andrea Goren	officer: Chief Financial Officer	110 EAST 59TH STREET, SUITE 1901, NEW YORK NY 10022
Barbara Ryan	director	22 CAVRAY ROAD, NORWALK CT 06855
Michael Jos. Campbell	director	61 SOUTH HILLS DRIVE, BEDFORD NH 03110
Rebecca Messina	director	5582 BROADCAST COURT, SARASOTA FL 34240
Jeffrey Segal	director	INVO BIOSCIENCE, INC., 5582 BROADCAST COURT, SARASOTA FL 34240
Awm Investment Company, Inc.	10 percent owner	527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Kevin Doody	director, officer: Medical Director	1109 SOMERSET BLVD, COLLEYVILLE TX 76034
Debra Robbins Hoopes	officer: Acting CFO and PFO	1 MORTON DR., SUITE 200, CHARLOTTESVILLE VA 22903
Claude Ranoux	10 percent owner	8 CHESTNUT STREET, WINCHESTER MA 01890
Kathleen T Karloff	director, officer: CEO/Chairman	109 BEACON STREET UNIT 5, BOSTON MA 02116
Bowdring Robert Joseph Jr	officer: Chief Financial Officer	92 GOULD STREET, WAKEFIELD MA 01880